Loading...
Loading...
Browse all stories on DeepNewz
VisitInsmed's Brensocatib Achieves Positive Late-Stage Results, Shares Surge 155%, Peaking at +132%
May 28, 2024, 10:39 AM
Insmed announced that its experimental drug, brensocatib, achieved positive topline results in the Phase 3 ASPEN study for treating bronchiectasis. The study met its primary endpoint for both dosage strengths, showing a statistically significant and clinically meaningful reduction in the frequency of respiratory symptoms such as chronic cough. As a result, Insmed's shares surged by 155% in pre-market trading, with a peak increase of 132%. Analysts from Truist project peak unadjusted sales of approximately $4 billion for brensocatib in bronchiectasis, with a potential fair value of around $74 per share. The success of this late-stage study marks a significant milestone for Insmed, positioning brensocatib as a promising treatment for chronic lung diseases.
View original story
Exceed $500 million • 25%
Between $300 million and $500 million • 25%
Between $100 million and $300 million • 25%
Below $100 million • 25%
Increase by over 50% • 25%
Increase by less than 50% • 25%
Decrease • 25%
Remain stable (±10%) • 25%
Significant stock price increase (over 15%) • 25%
Moderate stock price increase (5-15%) • 25%
Little to no change (0-5%) • 25%
Stock price decrease • 25%
Significant stock price increase (>15%) • 25%
Moderate stock price increase (5-15%) • 25%
Little to no change (<5%) • 25%
Stock price decrease • 25%
Phase 4 trial • 25%
Approval in additional markets • 25%
Development of new formulations • 25%
Strategic partnership or collaboration • 25%
Increase over 20% • 25%
Increase 10-20% • 25%
Decrease 10-20% • 25%
Decrease over 20% • 25%
Below IPO price • 25%
Equal to IPO price • 25%
1% to 10% above IPO price • 25%
More than 10% above IPO price • 25%
Increase by more than 5% • 25%
Increase by less than 5% • 25%
Decrease by less than 5% • 25%
Decrease by more than 5% • 25%
Below $50 • 33%
Between $50 and $100 • 33%
Above $100 • 33%
Above $5 billion • 25%
Below $1 billion • 25%
Between $1 billion and $3 billion • 25%
Between $3 billion and $5 billion • 25%